Key result
End-stage heart failure shows altered metabolism, heightened oxidative stress, and purine breakdown regardless of etiology.
Why the study?
Heart failure is linked to metabolic disturbances, but direct comparison of myocardial metabolomic changes between human end-stage ischemic and nonischemic heart failure is scarce.
Observational (n=40)
End-stage heart failure exhibits a shared metabolic remodeling profile characterized by altered glucose and amino acid metabolism and heightened oxidative stress, regardless of ischemic or non-ischemic etiology.
No takes yet. Share an insight, caveat, or question.
Metabolic profiling does not yet inform etiology-specific management in end-stage HF; hypothesis-generating for shared therapeutic targets across ischemic and nonischemic disease.
Zhou et al. (2026) conducted an observational in End-stage ischemic and non-ischemic cardiomyopathy (n=40). End-stage ischemic and non-ischemic cardiomyopathy vs. Nonfailing donors was evaluated on Metabolomic changes in myocardial tissues. End-stage heart failure showed altered glucose and amino acid metabolism, heightened oxidative stress, and increased purine breakdown, with no differences between ischemic and nonischemic etiologies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: